220 related articles for article (PubMed ID: 25186177)
1. Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases.
Wan X; Corn PG; Yang J; Palanisamy N; Starbuck MW; Efstathiou E; Li Ning Tapia EM; Zurita AJ; Aparicio A; Ravoori MK; Vazquez ES; Robinson DR; Wu YM; Cao X; Iyer MK; McKeehan W; Kundra V; Wang F; Troncoso P; Chinnaiyan AM; Logothetis CJ; Navone NM
Sci Transl Med; 2014 Sep; 6(252):252ra122. PubMed ID: 25186177
[TBL] [Abstract][Full Text] [Related]
2. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
André F; Bachelot T; Campone M; Dalenc F; Perez-Garcia JM; Hurvitz SA; Turner N; Rugo H; Smith JW; Deudon S; Shi M; Zhang Y; Kay A; Porta DG; Yovine A; Baselga J
Clin Cancer Res; 2013 Jul; 19(13):3693-702. PubMed ID: 23658459
[TBL] [Abstract][Full Text] [Related]
3. A 3D in vitro model of patient-derived prostate cancer xenograft for controlled interrogation of in vivo tumor-stromal interactions.
Fong EL; Wan X; Yang J; Morgado M; Mikos AG; Harrington DA; Navone NM; Farach-Carson MC
Biomaterials; 2016 Jan; 77():164-72. PubMed ID: 26599623
[TBL] [Abstract][Full Text] [Related]
4. Dovitinib reduces prostate cancer bone metastases.
Cancer Discov; 2014 Nov; 4(11):OF3. PubMed ID: 25367965
[No Abstract] [Full Text] [Related]
5. Prostate cancer: targeting the FGFR curbs bone metastasis.
Thoma C
Nat Rev Urol; 2014 Nov; 11(11):604. PubMed ID: 25245247
[No Abstract] [Full Text] [Related]
6. Bone-targeting agents in prostate cancer.
Suzman DL; Boikos SA; Carducci MA
Cancer Metastasis Rev; 2014 Sep; 33(2-3):619-28. PubMed ID: 24398856
[TBL] [Abstract][Full Text] [Related]
7. Dovitinib preferentially targets endothelial cells rather than cancer cells for the inhibition of hepatocellular carcinoma growth and metastasis.
Chen ZY; Shi M; Peng LX; Wei W; Li XJ; Guo ZX; Li SH; Zhong C; Qian CN; Guo RP
J Transl Med; 2012 Dec; 10():245. PubMed ID: 23228017
[TBL] [Abstract][Full Text] [Related]
8. Fibroblast Growth Factor Receptor 1 Drives the Metastatic Progression of Prostate Cancer.
Labanca E; Yang J; Shepherd PDA; Wan X; Starbuck MW; Guerra LD; Anselmino N; Bizzotto JA; Dong J; Chinnaiyan AM; Ravoori MK; Kundra V; Broom BM; Corn PG; Troncoso P; Gueron G; Logothethis CJ; Navone NM
Eur Urol Oncol; 2022 Apr; 5(2):164-175. PubMed ID: 34774481
[TBL] [Abstract][Full Text] [Related]
9. Combination treatment of prostate cancer with FGF receptor and AKT kinase inhibitors.
Feng S; Shao L; Castro P; Coleman I; Nelson PS; Smith PD; Davies BR; Ittmann M
Oncotarget; 2017 Jan; 8(4):6179-6192. PubMed ID: 28008155
[TBL] [Abstract][Full Text] [Related]
10. Combinatorial therapy using dovitinib and ICI182.780 (fulvestrant) blocks tumoral activity of endometrial cancer cells.
Eritja N; Domingo M; Dosil MA; Mirantes C; Santacana M; Valls J; Llombart-Cussac A; Matias-Guiu X; Dolcet X
Mol Cancer Ther; 2014 Apr; 13(4):776-87. PubMed ID: 24448819
[TBL] [Abstract][Full Text] [Related]
11. Ectopic fibroblast growth factor receptor 1 promotes inflammation by promoting nuclear factor-κB signaling in prostate cancer cells.
Wang C; Ke Y; Liu S; Pan S; Liu Z; Zhang H; Fan Z; Zhou C; Liu J; Wang F
J Biol Chem; 2018 Sep; 293(38):14839-14849. PubMed ID: 30093411
[TBL] [Abstract][Full Text] [Related]
12. Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells.
Konecny GE; Kolarova T; O'Brien NA; Winterhoff B; Yang G; Qi J; Qi Z; Venkatesan N; Ayala R; Luo T; Finn RS; Kristof J; Galderisi C; Porta DG; Anderson L; Shi MM; Yovine A; Slamon DJ
Mol Cancer Ther; 2013 May; 12(5):632-42. PubMed ID: 23443805
[TBL] [Abstract][Full Text] [Related]
13. Effect of transforming growth factor beta (TGF-β) receptor I kinase inhibitor on prostate cancer bone growth.
Wan X; Li ZG; Yingling JM; Yang J; Starbuck MW; Ravoori MK; Kundra V; Vazquez E; Navone NM
Bone; 2012 Mar; 50(3):695-703. PubMed ID: 22173053
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of prostate cancer osteoblastic progression with VEGF121/rGel, a single agent targeting osteoblasts, osteoclasts, and tumor neovasculature.
Mohamedali KA; Li ZG; Starbuck MW; Wan X; Yang J; Kim S; Zhang W; Rosenblum MG; Navone NM
Clin Cancer Res; 2011 Apr; 17(8):2328-38. PubMed ID: 21343372
[TBL] [Abstract][Full Text] [Related]
15. Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer.
Varkaris A; Corn PG; Parikh NU; Efstathiou E; Song JH; Lee YC; Aparicio A; Hoang AG; Gaur S; Thorpe L; Maity SN; Bar Eli M; Czerniak BA; Shao Y; Alauddin M; Lin SH; Logothetis CJ; Gallick GE
Clin Cancer Res; 2016 Jan; 22(1):107-21. PubMed ID: 26272062
[TBL] [Abstract][Full Text] [Related]
16. Targeting fibroblast growth factor receptor signaling inhibits prostate cancer progression.
Feng S; Shao L; Yu W; Gavine P; Ittmann M
Clin Cancer Res; 2012 Jul; 18(14):3880-8. PubMed ID: 22573348
[TBL] [Abstract][Full Text] [Related]
17. Tasquinimod inhibits prostate cancer growth in bone through alterations in the bone microenvironment.
Magnusson LU; Hagberg Thulin M; Plas P; Olsson A; Damber JE; Welén K
Prostate; 2016 Mar; 76(4):383-93. PubMed ID: 26660725
[TBL] [Abstract][Full Text] [Related]
18. Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.
Kotani H; Ebi H; Kitai H; Nanjo S; Kita K; Huynh TG; Ooi A; Faber AC; Mino-Kenudson M; Yano S
Oncogene; 2016 Jul; 35(27):3587-97. PubMed ID: 26549034
[TBL] [Abstract][Full Text] [Related]
19. Sabutoclax, a Mcl-1 antagonist, inhibits tumorigenesis in transgenic mouse and human xenograft models of prostate cancer.
Jackson RS; Placzek W; Fernandez A; Ziaee S; Chu CY; Wei J; Stebbins J; Kitada S; Fritz G; Reed JC; Chung LW; Pellecchia M; Bhowmick NA
Neoplasia; 2012 Jul; 14(7):656-65. PubMed ID: 22904682
[TBL] [Abstract][Full Text] [Related]
20. Targeting the heparin-binding domain of fibroblast growth factor receptor 1 as a potential cancer therapy.
Ling L; Tan SK; Goh TH; Cheung E; Nurcombe V; van Wijnen AJ; Cool SM
Mol Cancer; 2015 Jul; 14():136. PubMed ID: 26201468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]